Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01599286Phase 2Completed

Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia

Role: lead

NCT00843921Phase 2Unknown

N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia

Role: lead

NCT01597440Phase 2Terminated

Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia

Role: lead

All 3 trials loaded